Table 1

Baseline characteristics in the overall and biomarker populations

CharacteristicTreated patients
N=124
RNA-sequencing‒evaluable population
n=93
WES-evaluable population n=79
Responder, n (%)54 (43.5)38 (40.9)32 (40.5)
Median PFS, months (95% CI)7.4 (5.3 to 10.1)7.4 (5.3 to 9.7)7.4 (5.0 to 11.5)
Mean age, years (SD)65.3 (7.8)65.8 (7.7)66.0 (7.4)
Histology, n (%)
 Endometrioid adenocarcinoma67 (54.0)47 (50.5)38 (48.1)
 Serous adenocarcinoma39 (31.5)30 (32.3)27 (34.2)
 Clear cell adenocarcinoma6 (4.8)6 (6.5)4 (5.1)
 Adenocarcinoma NOS1 (0.8)1 (1.1)1 (1.3)
 Dedifferentiated/undifferentiated carcinoma1 (0.8)01 (1.3)
 Other10 (8.1)9 (9.7)8 (10.1)
ECOG performance status, n (%)
 062 (50.0)44 (47.3)38 (48.1)
 162 (50.0)49 (52.7)41 (51.9)
MSI-H status, n (%)
 MSI-H15 (12.1)10 (10.8)11 (13.9)
 MSS106 (85.5)83 (89.2)68 (86.1)
 Not available3 (2.4)00
PD-L1 status, n (%)
 Positive60 (48.4)50 (53.8)41 (51.9)
 Negative52 (41.9)42 (45.2)38 (48.1)
 Not available12 (9.7)1 (1.1)0
  • ECOG, Eastern Cooperative Oncology Group; MSI-H, microsatellite instability-high; MSS, microsatellite stable; NOS, not otherwise specified; PFS, progression-free survival; WES, whole-exome sequencing.